Oscar Tahuahua, Medical Oncology Fellow at the National Cancer Institute of Mexico, shared a post on X:
“Can we safely omit radiation in selected locally advanced rectal cancer?
The CONVERT trial randomized mesorectal fascia-negative patients to neoadjuvant CAPOX vs ChTR 3-year local control: 96.3% vs 97.4%. Non-inferiority was not formally met DFS/OS were similar between arms.
Long-term toxicity favored ChT alone. Careful selection may allow de-escalation w/o compromising outcomes.”
Title: Neoadjuvant Chemotherapy With CAPOX Versus Chemoradiation for Locally Advanced Rectal Cancer With Uninvolved Mesorectal Fascia (CONVERT): Final Results of a Phase III Trial
Authors: Wei-Jian Mei, Xiao-Zhong Wang, Xuan Zhang, Yue-Ming Sun, Chun-Kang Yang, Jun-Zhong Lin, Zu-Guang Wu, Rui Zhang, Wei Wang, Yong Li, Ye-Zhong Zhuang, Jian Lei, Xiang-Bin Wan, Ying-Kun Ren, Yong Cheng, Wen-Liang Li, Zi-Qiang Wang, Dong-Bo Xu, Xian-Wei Mo, Hai-Xing Ju, Sheng-Wei Ye, Jing-Lin Zhao, Hong Zhang, Yuan-Hong Gao, Zhi-Fan Zeng, Wei-Wei Xiao, Xiao-Peng Zhang, Yun-Feng Li, E Xie, Yi-Fei Feng, Jing-Hua Tang, Xiao-Jun Wu, Gong Chen, Li-Ren Li, Zhen-Hai Lu, De-Sen Wan, Jin-Xin Bei, Zhi-Zhong Pan, Jie-Hai Yu, Pei-Rong Ding
Read The Full Article
Other articles about CAPOX on OncoDaily.
